A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer(aEuro) Article

Industry Collaboration International Collaboration

cited authors

  • O'Neil, B. H.; Scott, A. J.; Ma, W. W.; Cohen, S. J.; Aisner, D. L.; Menter, A. R.; Tejani, M. A.; Cho, J. K.; Granfortuna, J.; Coveler, L.; Olowokure, O. O.; Baranda, J. C.; Cusnir, M.; Phillip, P.; Boles, J.; Nazemzadeh, R.; Rarick, M.; Cohen, D. J.; Radford, J.; Fehrenbacher, L.; Bajaj, R.; Bathini, V.; Fanta, P.; Berlin, J.; McRee, A. J.; Maguire, R.; Wilhelm, F.; Maniar, M.; Jimeno, A.; Gomes, C. L.; Messersmith, W. A.

authors

Publication Date

  • September 1, 2015

webpage

published in

category

keywords

  • III
  • PI3K inhibitor
  • PLK1 inhibitor
  • Ras mimetic
  • pancreatic cancer
  • phase II
  • rigosertib

start page

  • 1923

end page

  • 1929

volume

  • 26

issue

  • 9